Pharming Group N.V. (PHARM.AS)
EUR 0.8
(-3.32%)
EUR 0.8
(-3.32%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 123.65 Million EUR | -23.41% |
| 2022 | 161.46 Million USD | 2.65% |
| 2021 | 157.29 Million EUR | -0.57% |
| 2020 | 158.2 Million EUR | 3137.11% |
| 2019 | 4.88 Million EUR | -88.59% |
| 2018 | 42.81 Million EUR | -39.58% |
| 2017 | 70.87 Million EUR | 64.38% |
| 2016 | 43.11 Million EUR | 214.09% |
| 2015 | 13.72 Million EUR | 1069.75% |
| 2014 | 1.17 Million EUR | -29.59% |
| 2013 | 1.66 Million EUR | -35.73% |
| 2012 | 2.59 Million EUR | -9.66% |
| 2011 | 2.87 Million EUR | 0.0% |
| 2010 | - EUR | -100.0% |
| 2009 | 2.56 Million EUR | -95.13% |
| 2008 | 52.57 Million EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | -100.0% |
| 2005 | 165.81 Thousand EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 115.05 Million EUR | 0.0% |
| 2024 Q3 | 92.09 Million USD | 5.47% |
| 2024 Q1 | 28.43 Million USD | -100.0% |
| 2023 FY | 123.65 Million EUR | -23.41% |
| 2023 Q4 | 166.1 Million USD | 4.82% |
| 2023 Q3 | 158.46 Million USD | -3.66% |
| 2023 Q2 | 164.48 Million USD | -0.1% |
| 2023 Q1 | 164.65 Million USD | 1.98% |
| 2022 Q4 | 161.46 Million USD | 19.4% |
| 2022 Q2 | 144.88 Million USD | -5.59% |
| 2022 Q3 | 135.23 Million USD | -6.66% |
| 2022 FY | 161.46 Million USD | 2.65% |
| 2022 Q1 | 153.46 Million USD | 10.46% |
| 2021 Q2 | 165.83 Million EUR | 11.57% |
| 2021 FY | 157.29 Million EUR | -0.57% |
| 2021 Q3 | 160.27 Million EUR | -3.36% |
| 2021 Q4 | 138.93 Million EUR | -13.32% |
| 2021 Q1 | 148.64 Million EUR | -6.04% |
| 2020 FY | 158.2 Million EUR | 3137.11% |
| 2020 Q1 | 138.54 Million EUR | 2734.84% |
| 2020 Q2 | 143.23 Million EUR | 3.38% |
| 2020 Q3 | 150.62 Million EUR | 5.16% |
| 2020 Q4 | 158.2 Million EUR | 5.04% |
| 2019 Q4 | 4.88 Million EUR | -81.4% |
| 2019 Q3 | 26.27 Million EUR | -22.99% |
| 2019 FY | 4.88 Million EUR | -88.59% |
| 2019 Q2 | 34.11 Million EUR | -16.17% |
| 2019 Q1 | 40.69 Million EUR | -4.95% |
| 2018 Q2 | 55.62 Million EUR | -10.43% |
| 2018 Q3 | 48.35 Million EUR | -13.06% |
| 2018 FY | 42.81 Million EUR | -39.58% |
| 2018 Q4 | 42.81 Million EUR | -11.46% |
| 2018 Q1 | 62.09 Million EUR | -12.38% |
| 2017 Q1 | 36.5 Million EUR | -15.32% |
| 2017 FY | 70.87 Million EUR | 64.38% |
| 2017 Q4 | 70.87 Million EUR | -15.31% |
| 2017 Q3 | 83.68 Million EUR | -7.63% |
| 2017 Q2 | 90.6 Million EUR | 148.16% |
| 2016 FY | 43.11 Million EUR | 214.09% |
| 2016 Q1 | 12.59 Million EUR | -8.23% |
| 2016 Q4 | 43.11 Million EUR | 310.0% |
| 2016 Q2 | 11.5 Million EUR | -8.67% |
| 2016 Q3 | 10.51 Million EUR | -8.6% |
| 2015 Q3 | 16.1 Million EUR | 1504.57% |
| 2015 Q1 | 988.7 Thousand EUR | -15.74% |
| 2015 FY | 13.72 Million EUR | 1069.75% |
| 2015 Q2 | 1 Million EUR | 1.53% |
| 2015 Q4 | 13.72 Million EUR | -14.78% |
| 2014 Q3 | 1.36 Million EUR | -15.9% |
| 2014 FY | 1.17 Million EUR | -29.59% |
| 2014 Q2 | 1.62 Million EUR | 3.73% |
| 2014 Q4 | 1.17 Million EUR | -14.05% |
| 2014 Q1 | 1.56 Million EUR | -6.1% |
| 2013 Q2 | 2.41 Million EUR | 3.48% |
| 2013 FY | 1.66 Million EUR | -35.73% |
| 2013 Q4 | 1.66 Million EUR | -34.75% |
| 2013 Q3 | 2.55 Million EUR | 5.56% |
| 2013 Q1 | 2.33 Million EUR | -9.83% |
| 2012 Q4 | 2.59 Million EUR | -5.0% |
| 2012 Q1 | 2.69 Million EUR | -6.0% |
| 2012 FY | 2.59 Million EUR | -9.66% |
| 2012 Q3 | 2.72 Million EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 Q1 | - EUR | 0.0% |
| 2011 Q3 | - EUR | 0.0% |
| 2011 Q4 | 2.87 Million EUR | 0.0% |
| 2011 FY | 2.87 Million EUR | 0.0% |
| 2010 Q3 | 2.00 EUR | 199952022.53% |
| 2010 FY | - EUR | -100.0% |
| 2010 Q4 | - EUR | -100.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2010 Q1 | - EUR | -100.0% |
| 2009 FY | 2.56 Million EUR | -95.13% |
| 2009 Q4 | 2.56 Million EUR | 0.0% |
| 2008 FY | 52.57 Million EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | -100.0% |
| 2005 FY | 165.81 Thousand EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 1.1 Million EUR | -11131.359% |
| ABIVAX Société Anonyme | 44.69 Million EUR | -176.657% |
| Adocia SA | 4.54 Million EUR | -2623.728% |
| Aelis Farma SA | 2.04 Million EUR | -5937.952% |
| Biophytis S.A. | 3.11 Million EUR | -3874.84% |
| Advicenne S.A. | 15.89 Million EUR | -677.914% |
| genOway Société anonyme | 5.51 Million EUR | -2140.452% |
| IntegraGen SA | 642.28 Thousand EUR | -19152.86% |
| Medesis Pharma S.A. | 1.2 Million EUR | -10204.772% |
| Neovacs S.A. | 650 Thousand EUR | -18924.195% |
| NFL Biosciences SA | 39.2 Thousand EUR | -315328.072% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -2738.449% |
| Quantum Genomics Société Anonyme | 1.96 Million EUR | -6207.985% |
| Sensorion SA | 1.24 Million EUR | -9865.039% |
| Theranexus Société Anonyme | 2.46 Million EUR | -4925.251% |
| TME Pharma N.V. | - EUR | -Infinity% |
| Valbiotis SA | 3.89 Million EUR | -3072.326% |
| TheraVet SA | 1 Million EUR | -12258.324% |
| Valerio Therapeutics Société anonyme | 6.9 Million EUR | -1690.577% |
| argenx SE | 15.35 Million EUR | -705.375% |
| BioSenic S.A. | 15.57 Million EUR | -694.049% |
| Celyad Oncology SA | 902 Thousand EUR | -13609.231% |
| DBV Technologies S.A. | 4.52 Million USD | -2632.153% |
| Galapagos NV | 4.94 Million EUR | -2401.158% |
| Genfit S.A. | 62.25 Million EUR | -98.637% |
| GeNeuro SA | 6.49 Million EUR | -1804.676% |
| Hyloris Pharmaceuticals SA | 344 Thousand EUR | -35846.88% |
| Innate Pharma S.A. | 30.6 Million EUR | -304.016% |
| Inventiva S.A. | 25.61 Million EUR | -382.734% |
| MaaT Pharma SA | 5.42 Million EUR | -2179.397% |
| MedinCell S.A. | 52.8 Million EUR | -134.199% |
| Nanobiotix S.A. | 41.66 Million EUR | -196.825% |
| Onward Medical N.V. | 16.3 Million EUR | -658.354% |
| Oryzon Genomics S.A. | 3.45 Million EUR | -3483.63% |
| OSE Immunotherapeutics SA | 35.5 Million EUR | -248.252% |
| Oxurion NV | 117 Thousand EUR | -105589.972% |
| Poxel S.A. | 40.14 Million EUR | -208.042% |
| GenSight Biologics S.A. | 1.04 Million EUR | -11699.358% |
| Transgene SA | 17 Thousand EUR | -727295.688% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 2.87 Billion EUR | 95.703% |
| Valneva SE | 132.76 Million EUR | 6.862% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |